How Long Can You Live with Heart Failure?

Congestive heart failure (CHF) occurs when the heart can’t pump an adequate amount of blood to the body. The outlook for people with this condition is generally poor despite advances in treatment. The survival rate of a person with CHF depends how the well the heart is functioning, the presence of other diseases, age, CHF stage, and the person’s response to treatment.

Health conditions that can contribute to CHF include coronary artery disease, high blood pressure, heart valve disease, alcoholism, or a previous heart attack.

nurse listening to a woman's heartbeat

Eternity in an Instant / Getty Images

Overall Survival

Congestive heart failure is a chronic and progressive condition where the heart is weakened and unable to pump adequate oxygen- and nutrient-rich blood that your body’s cells need to function.

In the early stages of CHF, the heart muscle stretches and develops more muscle mass, therefore contracting with more force to pump more blood. After a period of time, the heart enlarges and can’t manage its workload, which leads to fatigue, shortness of breath, increased heart rate, leg swelling, and other symptoms.  

Congestive heart failure is broken down into four stages, ranging from high risk of developing heart failure to advanced heart failure. As symptoms worsen, so does CHF, moving on to the next stage.

The prognosis of CHF is broken down into increments of five-year mortality rates—an assessment that estimates short- and long-term survival rates from the time of a person’s CHF diagnosis and treatment.

Five-Year Survival Rate

Approximately 6.2 million adults in the United States have been diagnosed with heart failure with a five-year survival rate of about 50% for all stages. In 2018, 379,800 deaths were determined to be a result of heart failure. Geographically, heart failure is widespread in certain regions of the United States, primarily the South and Midwest.

Studies that examined prognosis of chronic heart failure in patients in a managed community environment or in an outpatient setting showed the following survival rates for persons with CHF: 80-90%, (97% of the general population for the first year); 50-60% by the fifth year, (85% of the general population); and 30% by year 10—those with heart failure and left ventricular systolic dysfunction (LVSD) (75% of the general population.) 

Prognosis by Stage

Prognosis depends on the stage and cause of CHF and a person’s age, sex, and socioeconomic status. The different stages of CHF include:

  • Stage A: High risk for heart failure, but without structural heart disease or symptoms of heart failure
  • Stage B: Structural heart disease, but without signs or symptoms of heart failure
  • Stage C: Structural heart disease with prior or current symptoms of heart failure. This stage can be further categorized into two stages: Early-stage C1 is clinical heart failure without prior hospitalization, while advanced-stage C2 refers to clinical heart failure with prior hospitalization

Absolute mortality rates remaining at about 50% within five years of diagnosis of CHF. Five-year mortality data for each of the four stages of CHF are: 

Five-Year Survival Rates
 Stage  5-Year Survival Rate
 Stage A  97%
 Stage B  95.7%
 Stage C (Both C1 and C2  74.6%
 Early-Stage C1  78%
 Advance Stage C2  60%
 Stage D  20%

Factors Affecting Survival

Numerous factors may affect a person’s survival rate, including age, sex, exercise tolerance, and other medical conditions.


Heart failure typically affects older adults (middle-age and older). Among Medicare patients, it is the leading cause for hospitalization. Complications of CHF also steadily increase with age.

A clinical trial found that the rate of hospitalization decreased over time for patients aged 65 and older, but grew among people 20-65 years old. Mortality rates were lower for patients in the 20-44 group, who were found to be less likely to be admitted to the emergency room or hospitalized for heart failure or other cardiac issues. Their mortality rates were still significant in 30 days (3.9%), one year (12.4%), and five years (27.7%). The study concluded that serious CHF occurrences were more frequent in 50% of people who were readmitted to the hospital (two-thirds went to the emergency room, and more than 10% died within 12 months).


Women with CHF tend to live longer than men when the cause isn’t ischemia (an inadequate blood supply to the heart muscles); women with nonischemic heart failure have a better chance of surviving than men either with or without heart disease as their main cause of heart failure. 

Comorbidities found in women with heart failure—especially those who are post-menopause—include hypertension, valvular heart disease, diabetes, and coronary artery disease. Once coronary heart disease has been diagnosed, the risk of HF increases. 

Exercise Tolerance

Exercise intolerance is defined by not only a reduction in maximal oxygen uptake, the maximum amount of oxygen a person can use during an intense workout, but also the restricted capability to carry out any physical activity. CHF symptoms include labored breathing and fatigue. In addition, low exercise tolerance is a key symptom in CHF that is associated with poor quality of life and an increased mortality rate.

Contributors of exercise intolerance include:

  • Reduced cardiovascular reserve
  • Reduced pulmonary reserve
  • Structural and/or functional skeletal muscle malformations

Other factors such as anemia and obesity also play a role in exercise tolerance. 

Three-year survival rates for patients with reduced exercise tolerance was 57%, compared with 93% in those with normal exercise tolerance.

Ejection Fraction

Ejection fraction measures the percentage of blood that is pumped out by the left ventricle with each contraction. Ejection fraction dysfunction can cause different types of heart failure, including: 

  • Preserved ejection fraction (HFpEF), or diastolic heart failure: The heart contracts normally, but the ventricles do not relax during ventricular filling
  • Reduced ejection fraction (HFrEF), or systolic heart failure: The heart does not contract sufficiently, leading to less oxygen-rich blood being pumped out to the body

Normal ejection fraction rates range between 50% and 70%. An ejection fraction between 41% and 49% falls in the borderline classification, which doesn’t necessarily indicate that the individual is developing heart failure, but may signal a damaged heart or a prior heart attack. An ejection fraction rate of 40% or lower may indicate heart failure or cardiomyopathy.  

Mortality rates for people with HFpEF were lower compared with people who have HFrFE. One trial showed that mortality rate increased proportionally with the decrease in the left ventricular ejection fraction with the following breakdown:

  • Under 15%: 51%
  • 16-25%: 41.7%
  • 26-35%: 31.4%
  • 35-45%: 25.6% 


Type 2 diabetes is considered an independent risk factor and increases morbidity and mortality rates of people with CHF. About 20-40% of heart failure patients have diabetes, and at least 10% of high-risk cardiovascular patients may have undiagnosed diabetes. 

According to a study that examined the frequency of diabetes and acute heart failure in a group of 400 patients, 203 men and 197 women with an average age of 71 years fell into the following glycemic distribution: 37% had clinical diabetes, 16% had undiagnosed diabetes, and 47% percent did not have diabetes. 

People with diabetes were more likely to have hypertension, dyslipidemia, peripheral vascular disease, and a previous heart attack. Those with undiagnosed diabetes were likely to have similar comorbidities as people without diabetes. However, individuals with diabetes and undiagnosed diabetes had more hospital stays due to acute heart failure from the prior year, with no differences in left ventricular ejection fraction. Yet the incidence of heart failure with systolic dysfunction (EF of less than 40%) was similar in all three groups.

Mortality rate of patients with undiagnosed diabetes were more likely to die 1.69 times more often than those without diabetes. Patients with undiagnosed diabetes showed a lower cardiovascular risk profile compared with people with diabetes, but mortality rates were similar between the two groups. 


Heart failure relapses that require hospitalization often indicate a bad outcome. These symptomatic relapses also point to progression of the condition. The 30 days after initial hospitalization are viewed as a high-risk period, and require intensive follow-up and monitoring.  

What You Can Do

Although some risk factors of heart failure like age can’t be modified, people with CHF can take actions to improve their long-term prognosis. The first step is to become familiar with any family history of heart disease and learn about the all the possible symptoms. Don't ignore suspicious symptoms, and let your doctor know. Regular exercise and managing concurrent conditions can help keep CHF under control.


People who are diagnosed with heart disease have no reduced mortality risk linked to weight loss, but ongoing and sustained physical activity are associated with considerable risk reduction.

Another study examined patients with diabetes who were hospitalized for heart failure. Of those patients, 65% were overweight or obese and 3% were underweight. Patients who were underweight and diabetic had a 50% chance to die within five years. The odds were lower by 20% to 40% for those with obesity than patients at normal weights. The inverse relationship between obesity and reduced mortality rate may be explained by the ages of the obese patients who were younger than patients who were of normal weight or underweight.

Weight Loss, Diabetes, and Obesity

A 2018 study published in the Canadian Journal of Diabetes recommends that a sustained weight loss of more than 5% of body weight will lead to an improvement in glycemic control and cardiovascular risk factors. By employing healthy lifestyle choices like exercise, eating a better diet, and other behavior interventions, both weight loss and lowering A1C can be reached. 

Medication to manage weight may improve glycemic and metabolic control in both people with diabetes and obese patients, and when deemed appropriate, bariatric surgery may be an option for obese and diabetic patients.

Before you begin any sort of weight loss program, consult with your cardiologist and diabetes management team first.

Diabetes Control

Diabetes is associated with the risk of developing heart failure. For people with diabetes, 25% of patients with chronic heart failure and up to 40% of these patients have acute heart failure. Heart failure is prioritized when treating both conditions at the same time. Consequently, people with diabetes and heart failure should be treated and managed by cardiologists. To reduce the risk of death, continued blood glucose control is also key. 

Some strategies to prevent or manage both type 1 and type 2 diabetes include the use of beta-blockers and angiotensin-converting enzyme inhibitors, which benefit patients and is linked with a lower mortality rate and fewer hospitalizations. Angiotensin II receptor blockers have shown similar effectiveness in heart failure patients with and without diabetes.


Mineralocorticoid receptor antagonists (diuretics) are recommended to symptomatic heart failure patients, along with a combination of ACE inhibitors/angiotensin receptor blockers (ARBs) and beta-blockers.

In a trial with patients with moderate to severe symptoms of heart failure, patients were given spironolactone (a potassium-sparing diuretic). After a follow-up of two years, there was a 30% risk reduction in all-cause mortality, a 35% decrease in rehospitalization, and a 36% decrease in progressive heart failure.

Therapy Effetiveness

Heart failure prognosis has improved due to new drug therapies. However, the effectiveness of these therapies can change over time. New symptoms, or worsening ones, that surface while on these treatments should be reported to your cardiologist for changes in your treatment. 

A Word From Verywell

Although the prognosis for CHF is unnerving, there are numerous lifestyle changes and medications that can slow down the progression of the condition and increase your chances of survival. You can be proactive in managing the condition by monitoring your symptoms, eliminating unhealthy habits, exercising regularly, and eating a healthy diet.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Heart failure: understanding heart failure outlook / prognosis. Cleveland Clinic.

  2. American Heart Association. What is heart failure?

  3. American Heart Association. Managing heart failure symptoms,

  4. Cleveland Clinic. Heart failure: understanding heart failure management and treatment,

  5. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FDR. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. 2019 Feb 13;364:l223. doi: 10.1136/bmj.l223

  6. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757

  7. Centers for Disease Control and Prevention. Heart Failure.

  8. Jones NR, Hobbs FR, Taylor CJ. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. BJGP Open. 2017 Oct 4;1(3):bjgpopen17X101013. doi: 10.3399/bjgpopen17X101013

  9. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776

  10. Kitzman DW, Rich MW. Age disparities in heart failure research. JAMA. 2010 Nov 3;304(17):1950-1. doi: 10.1001/jama.2010.1592

  11. Wong CM, Hawkins NM, Ezekowitz JA, Jhund PS, Savu A, MacDonald MR, Kristensen SL, Petrie MC, McMurray JJV, McAlister FA, Kaul P. Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. Can J Cardiol. 2017 Nov;33(11):1472-1477. doi: 10.1016/j.cjca.2017.05.009

  12. Bozkurt B, Khalaf S. Heart Failure in Women. Methodist Debakey Cardiovasc J. 2017 Oct-Dec;13(4):216-223. doi: 10.14797/mdcj-13-4-216

  13. Del Buono MG, Arena R, Borlaug BA, Carbone S, Canada JM, Kirkman DL, Garten R, Rodriguez-Miguelez P, Guazzi M, Lavie CJ, Abbate A. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 May 7;73(17):2209-2225. doi: 10.1016/j.jacc.2019.01.072

  14. Ponikowski P, Francis DP, Piepoli MF, Davies LC, Chua TP, Davos CH, Florea V, Banasiak W, Poole-Wilson PA, Coats AJ, Anker SD. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation. 2001 Feb 20;103(7):967-72. doi: 10.1161/01.cir.103.7.967

  15. American Heart Association. Ejection fraction heart failure measurement.

  16. Bytyçi I, Bajraktari G. Mortality in heart failure patients. Anatol J Cardiol. 2015 Jan;15(1):63-8. doi: 10.5152/akd.2014.5731

  17. Flores-Le Roux JA, Comin J, Pedro-Botet J, Benaiges D, Puig-de Dou J, Chillarón JJ, Goday A, Bruguera J, Cano-Perez JF. Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study. Cardiovasc Diabetol. 2011 May 14;10:39. doi: 10.1186/1475-2840-10-39

  18. Jones NR, Hobbs FR, Taylor CJ. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. BJGP Open. 1(3). DOI: 10.3399/bjgpopen17X101013

  19. Moholdt T, Lavie CJ, Nauman J. Sustained Physical Activity, Not Weight Loss, Associated With Improved Survival in Coronary Heart Disease. J Am Coll Cardiol. 2018 Mar 13;71(10):1094-1101. doi: 10.1016/j.jacc.2018.01.011

  20. Waring ME, Saczynski JS, McManus D, Zacharias M, Lessard D, Gore JM, Goldberg RJ. Weight and mortality following heart failure hospitalization among diabetic patients. Am J Med. 2011 Sep;124(9):834-40. doi: 10.1016/j.amjmed.2011.04.030

  21. Rosano GM, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev. 2017 Apr;3(1):52-55. doi: 10.15420/cfr.2016:20:2

  22. Frankenstein L, Katus HA, Grundtvig M, Hole T, de Blois J, Schellberg D, Atar D, Zugck C, Agewall S; Norwegian Heart Failure Registry steering committee. Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study. Eur J Clin Pharmacol. 2013 Oct;69(10):1747-55. doi: 10.1007/s00228-013-1512-x

  23. American College of Cardiology. Should all patients with hf get aldosterone blockade. Published August 19, 2011.